<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702608</url>
  </required_header>
  <id_info>
    <org_study_id>EluNIR-004</org_study_id>
    <nct_id>NCT03702608</nct_id>
  </id_info>
  <brief_title>BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial</brief_title>
  <official_title>Prospective, Multi-center, Single-arm, Open-label Clinical Trial, to Further Assess the Safety and Efficacy of Long (38 mm) Ridaforolimus Eluting Stent - EluNIR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medinol Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medinol Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single-arm, open-label clinical trial. Clinical&#xD;
      follow-up will be performed at 30 days. Follow-up by phone will be performed at 6 months, and&#xD;
      1 year after the procedure. Study Objective is to further assess the safety and efficacy of&#xD;
      long (38 mm) Ridaforolimus Eluting Stent - EluNIR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint: Device Success</measure>
    <time_frame>30 day</time_frame>
    <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA), using the assigned device only and without a device malfunction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint: No 30 Day MACE (Major Adverse Cardiac Events)</measure>
    <time_frame>30 Day</time_frame>
    <description>No 30 day MACE: MACE (Major Adverse Cardiac Events) is defined as the composite of cardiac death, any MI, or ischemia-driven TLR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>EluNIR 38mm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EluNIR Ridaforolimus Eluting Coronary Stent System</intervention_name>
    <description>The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - (PBMA) and CarboSil®&#xD;
Ridaforolimus drug</description>
    <arm_group_label>EluNIR 38mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General Inclusion Criteria:&#xD;
&#xD;
               1. Age ≥ 18 years.&#xD;
&#xD;
               2. Patient with an indication for PCI including angina (stable or unstable), silent&#xD;
                  ischemia (in absence of symptoms a visually estimated target lesion diameter&#xD;
                  stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be&#xD;
                  present), NSTEMI, or recent STEMI. For STEMI the time of presentation to the&#xD;
                  first treating hospital, whether a transfer facility or the study hospital, must&#xD;
                  be &gt;24 hours prior to enrollment and enzyme levels (CK-MB or Troponin)&#xD;
                  demonstrating that either or both enzyme levels have peaked.&#xD;
&#xD;
               3. An attempt (whether successful or not) was made to implant a 38 mm EluNIR stent&#xD;
                  (Stent was advanced beyond the guiding catheter).&#xD;
&#xD;
               4. Non-target vessel PCI are allowed prior to the screening for eligibility&#xD;
                  depending on the time interval and conditions as follows:&#xD;
&#xD;
                    1. During Baseline Procedure:&#xD;
&#xD;
                       PCI of non-target vessels performed during the baseline procedure itself&#xD;
                       immediately prior to screening for eligibility, if successful and&#xD;
                       uncomplicated defined as: &lt;50% visually estimated residual diameter&#xD;
                       stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C, no perforation,&#xD;
                       no persistent ST segment changes, no prolonged chest pain, no TIMI major or&#xD;
                       BARC type 3 bleeding.&#xD;
&#xD;
                    2. Less than 24 hours prior to Baseline Procedure:&#xD;
&#xD;
                  Not allowed (see exclusion criteria #2). c. 24 hours-30 days prior to Baseline&#xD;
                  Procedure: i. PCI of non-target vessels 24 hours to 30 days prior to the baseline&#xD;
                  procedure if successful and uncomplicated as defined above.&#xD;
&#xD;
                  ii. In addition, in cases where non-target lesion PCI has occurred 24-72 hours&#xD;
                  prior to the baseline procedure, at least 2 sets of cardiac biomarkers must have&#xD;
                  been drawn at least 6 and 12 hours after the non-target vessel PCI.&#xD;
&#xD;
                  iii. If cardiac biomarkers are initially elevated above the local laboratory&#xD;
                  upper limit of normal, serial measurements must demonstrate that the biomarkers&#xD;
                  are falling.&#xD;
&#xD;
                  d. Over 30 days prior to Baseline Procedure: PCI of non-target vessels performed&#xD;
                  greater than 30 days prior to baseline procedure whether or not successful and&#xD;
                  uncomplicated.&#xD;
&#xD;
               5. Patient or legal guardian is willing and able to provide informed written consent&#xD;
                  and comply with follow-up visits and testing schedule.&#xD;
&#xD;
                  Angiographic inclusion criteria (visual estimate):&#xD;
&#xD;
               6. Target lesion(s) must be located in a native coronary artery or bypass graft&#xD;
                  conduit with visually estimated diameter of ≥2.75 mm to ≤4.25 mm.&#xD;
&#xD;
               7. Complex lesions are allowed including calcified lesions (lesion preparation with&#xD;
                  scoring/cutting and rotational atherectomy are allowed), presence of thrombus,&#xD;
                  CTO, bifurcation lesions, ostial RCA lesions, tortuous lesions, bare metal stent&#xD;
                  restenotic lesions, protected left main lesions, and saphenous vein graft&#xD;
                  lesions.&#xD;
&#xD;
               8. Overlapping stents are allowed as long as the first stent implanted is the EluNIR&#xD;
                  38 mm long stent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General Exclusion Criteria:&#xD;
&#xD;
               1. STEMI within 24 hours of initial time of presentation to the first treating&#xD;
                  hospital, whether at a transfer facility or the study hospital or in whom enzyme&#xD;
                  levels (either CK-MB or Troponin) have not peaked.&#xD;
&#xD;
               2. PCI within the 24 hours preceding the baseline procedure.&#xD;
&#xD;
               3. Non-target lesion PCI in the target vessel within 12 months of the baseline&#xD;
                  procedure.&#xD;
&#xD;
               4. History of stent thrombosis.&#xD;
&#xD;
               5. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure &lt;90&#xD;
                  mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support,&#xD;
                  including IABP.&#xD;
&#xD;
               6. Subject is intubated.&#xD;
&#xD;
               7. Known LVEF &lt;30%.&#xD;
&#xD;
               8. Relative or absolute contraindication to DAPT for 6 months in non-ACS patients&#xD;
                  and 12 months in ACS patients (including planned surgeries that cannot be&#xD;
                  delayed, or subject is indicated for chronic oral anticoagulant treatment).&#xD;
&#xD;
               9. eGFR &lt;30 mL/min&#xD;
&#xD;
              10. Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
              11. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3.&#xD;
&#xD;
              12. White blood cell (WBC) count &lt;3,000 cells/mm3.&#xD;
&#xD;
              13. Clinically significant liver disease.&#xD;
&#xD;
              14. Active peptic ulcer or active bleeding from any site.&#xD;
&#xD;
              15. Bleeding from any site within the prior 8 weeks requiring active medical or&#xD;
                  surgical attention.&#xD;
&#xD;
              16. If femoral access is planned, significant peripheral arterial disease which&#xD;
                  precludes safe insertion of a 6F sheath.&#xD;
&#xD;
              17. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.&#xD;
&#xD;
              18. Cerebrovascular accident or transient ischemic attack within the past 6 months,&#xD;
                  or any permanent neurologic defect attributed to CVA.&#xD;
&#xD;
              19. Known allergy to the study stent components cobalt, nickel, chromium, molybdenum,&#xD;
                  Carbosil®, PBMA, or limus drugs (ridaforolimus, zotarolimus, tacrolimus,&#xD;
                  sirolimus, everolimus, or similar drugs or any other analogue or derivative or&#xD;
                  similar compounds).&#xD;
&#xD;
              20. Known allergy to protocol-required concomitant medications such as aspirin, or&#xD;
                  DAPT (clopidogrel, prasugrel, ticagrelor), or heparin and bivalirudin, or&#xD;
                  iodinated contrast that cannot be adequately pre-medicated.&#xD;
&#xD;
              21. Any co-morbid condition that may cause non-compliance with the protocol (e.g.&#xD;
                  dementia, substance abuse, etc.) or reduced life expectancy to &lt;24 months (e.g.&#xD;
                  cancer, severe heart failure, severe lung disease).&#xD;
&#xD;
              22. Patient is participating in or plans to participate in any other investigational&#xD;
                  drug or device clinical trial that has not reached its primary endpoint.&#xD;
&#xD;
              23. Women who are pregnant or breastfeeding.&#xD;
&#xD;
              24. Women who intend to become pregnant within 12 months after the baseline procedure&#xD;
                  (women of child-bearing potential who are sexually active must agree to use a&#xD;
                  reliable method of contraception from the time of screening through 12 months&#xD;
                  after the baseline procedure).&#xD;
&#xD;
              25. Patient has received an organ transplant or is on a waiting list for an organ&#xD;
                  transplant.&#xD;
&#xD;
              26. Patient is receiving or scheduled to receive chemotherapy within 30 days before&#xD;
                  or any time after the baseline procedure.&#xD;
&#xD;
              27. Patient is receiving oral or intravenous immunosuppressive therapy or has known&#xD;
                  life-limiting immunosuppressive or autoimmune disease (e.g., HIV).&#xD;
                  Corticosteroids are allowed.&#xD;
&#xD;
                  Angiographic Exclusion Criteria (visual estimate):&#xD;
&#xD;
              28. Unprotected left main lesions ≥30%, or planned left main intervention.&#xD;
&#xD;
              29. Bifurcation lesions with planned dual stent implantation.&#xD;
&#xD;
              30. Stenting of lesions due to DES restenosis.&#xD;
&#xD;
              31. Occlusive thrombus and/or a thrombus requiring thrombectomy in a target vessel&#xD;
&#xD;
              32. Another lesion in a target or non-target vessel (including all side branches) is&#xD;
                  present that requires or has a high probability of requiring PCI within 12 months&#xD;
                  after the baseline procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medinol LTD</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>October 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2020</results_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03702608/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03702608/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EluNIR 38mm</title>
          <description>Patients received the EluNIR Ridaforolimus Eluting Coronary Stent System: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - (PBMA) and CarboSil®&#xD;
Ridaforolimus drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with an indication for PCI including angina (stable or unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, or recent STEMI.</population>
      <group_list>
        <group group_id="B1">
          <title>EluNIR 38mm</title>
          <description>Patients received the EluNIR Ridaforolimus Eluting Coronary Stent System: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - (PBMA) and CarboSil®&#xD;
Ridaforolimus drug</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoint: Device Success</title>
        <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA), using the assigned device only and without a device malfunction.</description>
        <time_frame>30 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EluNIR 38mm</title>
            <description>EluNIR Ridaforolimus Eluting Coronary Stent System: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - (PBMA) and CarboSil®&#xD;
Ridaforolimus drug</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoint: Device Success</title>
          <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA), using the assigned device only and without a device malfunction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoint: No 30 Day MACE (Major Adverse Cardiac Events)</title>
        <description>No 30 day MACE: MACE (Major Adverse Cardiac Events) is defined as the composite of cardiac death, any MI, or ischemia-driven TLR.</description>
        <time_frame>30 Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EluNIR 38mm</title>
            <description>EluNIR Ridaforolimus Eluting Coronary Stent System: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - (PBMA) and CarboSil®&#xD;
Ridaforolimus drug</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoint: No 30 Day MACE (Major Adverse Cardiac Events)</title>
          <description>No 30 day MACE: MACE (Major Adverse Cardiac Events) is defined as the composite of cardiac death, any MI, or ischemia-driven TLR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Investigator monitored the occurrence of adverse events or device deficiencies for each subject during the whole course of the trial- baseline and post procedure, 30 days, 6 months and 1 year visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EluNIR 38mm</title>
          <description>Patients received the EluNIR Ridaforolimus Eluting Coronary Stent System: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - (PBMA) and CarboSil®&#xD;
Ridaforolimus drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dina Kofler, VP Clinical Affairs</name_or_title>
      <organization>Medinol</organization>
      <phone>+97237679032</phone>
      <email>dinak@medinol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

